The related MK-1903, a partial agonist of HCAR2 developed by Merck, passed into Phase 2 clinical trials as a treatment for atherosclerosis and dyslipidemia, but was dropped from further development because the observed elevation of HDL cholesterol did not meet the target criteria (https://drugs.ncats.io/drug/62N05GRI0P). This evidence concerns the gene HCAR2 and atherosclerosis.